Evidence map›Paper›PMID 23634944›Full record

ArticleNucleic acid therapeutics2013

Telomere-homologous G-rich oligonucleotides sensitize human ovarian cancer cells to TRAIL-induced growth inhibition and apoptosis.

Sibaji Sarkar, Douglas V Faller

Open access · greenAbstract read
In one paragraph

Article in Nucleic acid therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Treating Cancer by Targeting Telomeres and Telomerase.Antioxidants (Basel, Switzerland) · 2017
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Cancer development, progression, and therapy: an epigenetic overview.International journal of molecular sciences · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Sibaji SarkarCancer Center, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
Douglas V Faller
Boston University · USUniversity School · US

Funding

Inducing Chromosomal Damage Responses in Pancreatic CancerR21CA133654 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FALLER, DOUGLAS V · 2009 to 2010
$393k
NCI NIH HHS CA133654
6 · The paper itself

Abstract

G-rich T-oligos (GT-oligos; oligonucleotides with homology to telomeres) elicit a DNA damage response in cells and induce cytotoxic effects in certain tumor cell lines. We have previously shown that GT-oligo inhibits growth, arrests cell cycle, and induces apoptosis in ovarian, pancreatic, and prostate cancer cells. However, not all ovarian cancer cell lines are susceptible to GT-oligo exposure. GT-oligo was found to induce transcript expression of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors DR-4 and DR-5, which are generally silenced in ovarian cancer cells, rendering them insensitive to TRAIL. Exposure of TRAIL- and GT-oligo-resistant cell lines to GT-oligo rendered them sensitive to the cytotoxic effects of TRAIL, producing more than additive inhibition of growth. An intracellular inhibitor of the extrinsic apoptotic pathway, FLICE-like Inhibitory Protein-Short (FLIPs), was down-regulated and Jun kinase (JNK) was activated by exposure to GT-oligo. JNK inhibition partially reversed the growth inhibition caused by the combination of GT-oligo and TRAIL indicating partial involvement of the Jun kinase pathway in the resulting cytotoxic effect. Both capase-8 and caspases 3/7 were activated by exposure to GT-oligo plus TRAIL, consistent with activation of the extrinsic apoptotic pathway. These results demonstrate a novel way of sensitizing resistant ovarian cancer cells to TRAIL-mediated cytotoxicity.

Indexed as

Antineoplastic AgentsApoptosisCASP8 and FADD-Like Apoptosis Regulating ProteinCaspase 3Caspase 7Caspase 8Cell Line, TumorCell SurvivalDrug SynergismFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMAP Kinase Kinase 4OligonucleotidesOvarian NeoplasmsAntineoplastic AgentsCASP8 and FADD-Like Apoptosis Regulating ProteinCASP8 protein, humanCaspase 3Caspase 7Caspase 8MAP Kinase Kinase 4OligonucleotidesReceptors, TNF-Related Apoptosis-Inducing LigandRecombinant ProteinsTNF-Related Apoptosis-Inducing LigandTNFRSF10A protein, humanTNFSF10 protein, human

Identifiers

PMID23634944
PMCPMC3660071
OpenAlexW1500005278

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.